<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study was purposed to investigate the clinical efficiencies and adverse reactions of treating the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) by using <z:chebi fb="0" ids="50131">decitabine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical data of 12 MDS and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients treated with <z:chebi fb="0" ids="50131">decitabine</z:chebi> were analyzed retrospectively </plain></SENT>
<SENT sid="2" pm="."><plain>Among 12 patients there were 1 case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA, 2 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-I</z:e>, 3 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e>, 2 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M4, 2 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M5, 1 case of <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e> and 1 case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M0 </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:chebi fb="0" ids="50131">decitabine</z:chebi> chemotherapy program for 5 days (n = 8), <z:chebi fb="0" ids="50131">decitabine</z:chebi> 20 mg/(m(2)·d) × 5 days was applied, 4 weeks for 1 cycle; in program for 3 days (n = 2), <z:chebi fb="0" ids="50131">decitabine</z:chebi> 15 mg/m(2), once 8 h for 3 days, 6 weeks for 1 cycle; another program (n = 2), <z:chebi fb="0" ids="50131">decitabine</z:chebi> 20 mg/(m(2)·d) every other day for 5 times </plain></SENT>
<SENT sid="4" pm="."><plain>For 1 patient achieved complete remission (CR) after treatment with decitbine, ID4 gene methylated level was detected by MS-PCR and ML-PCR before and after treatment </plain></SENT>
<SENT sid="5" pm="."><plain>The results showed that 2 cases achieved CR, 1 case partial remission, 5 cases stable disease, 1 case progress of disease and 3 cases died </plain></SENT>
<SENT sid="6" pm="."><plain>Disease control rate was 66.67% (8/12), the effective rate 25% (3/12) </plain></SENT>
<SENT sid="7" pm="."><plain>The average survival time was (11.5 ± 2.1) months </plain></SENT>
<SENT sid="8" pm="."><plain>1-year OS rate was 40%, 2-year OS rate was 16.7% </plain></SENT>
<SENT sid="9" pm="."><plain>MS-PCR detection showed that the <z:chebi fb="0" ids="50131">decitabine</z:chebi> could significantly reduce the ID4 gene methylation level </plain></SENT>
<SENT sid="10" pm="."><plain>It is concluded that <z:chebi fb="0" ids="50131">decitabine</z:chebi> can stabilize disease status of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, reduce blood transfusion dependence and improve the life quality of patients, and even some patients who transformed from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to <z:hpo ids='HP_0001909'>leukemia</z:hpo> achieved CR after treatment with <z:chebi fb="0" ids="50131">decitabine</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> can reduce the ID4 gene methylation level </plain></SENT>
<SENT sid="12" pm="."><plain>The main adverse reaction of <z:chebi fb="0" ids="50131">decitabine</z:chebi> was <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and so on </plain></SENT>
<SENT sid="13" pm="."><plain>So the blood transfusions, antibiotics and other supportive treatments for these patients are needed </plain></SENT>
<SENT sid="14" pm="."><plain>Most of patients well tolerate the adverse effects of <z:chebi fb="0" ids="50131">decitabine</z:chebi> after active symptomatic and supportive treatment </plain></SENT>
<SENT sid="15" pm="."><plain>The efficacy and survival rate of patients in this study were similar to that of application of <z:chebi fb="0" ids="50131">decitabine</z:chebi> to treat <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in other domestic studies </plain></SENT>
</text></document>